DDInter704 DDInter36
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Albiglutide
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Acarbose {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Everolimus {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Albiglutide
Everolimus {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Liotrix
Liotrix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Albiglutide
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Paliperidone
Paliperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Albiglutide
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Albiglutide
Everolimus {u} (Compound) downregulates {v} (Gene) JADE2
JADE2 {u} (Gene) is upregulated by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Everolimus {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Warfarin (Compound) and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Everolimus (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Everolimus (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Liotrix (Compound) and Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paliperidone (Compound) and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Everolimus (Compound) downregulates JADE2 (Gene) and JADE2 (Gene) is upregulated by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Everolimus (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Simvastatin (Compound) and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Albiglutide